Topics

vaccine (or viral) immune escape (VIE)

A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections
Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 - A Multidisciplinary Perspective
Characteristics and predictors of Long COVID among diagnosed cases of COVID-19
Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants
Continued mass vaccination will only push the evolutionary capacity of SARS-CoV-2 Spike protein beyond the Omicron version
Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens
Interview excerpt with Luc Montagnier (2008 Nobel Prize in Medicine)
Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America
mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review
Ninety-third SAGE meeting on COVID-19
Open Letter to the World Health Organization
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
Proximal Origin of Epidemic Highly Pathogenic Avian Influenza H5N1 Clade 2.3.4.4b and Spread by Migratory Waterfowl
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
SARS-CoV2 vaccine and viral variant research library
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study
The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages
The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
Vaccines and Related Biological Products Advisory Committee, remarks by Dr. Jessica Rose
910